Enfortumab Vedotin and the Role of ADCs in Bladder Cancer
Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.
EP: 1.Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)
EP: 2.Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer
EP: 3.Monitoring Patients With NMIBC
EP: 4.Bladder Cancer: Treatment Options and Managing Adverse Effects
EP: 5.Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments
Now Viewing
EP: 6.Enfortumab Vedotin and the Role of ADCs in Bladder Cancer
EP: 7.Approach to Collaborative Care in Bladder Cancer
EP: 8.Key Takeaways on Evolving Bladder Cancer Treatment Landscape
Related Videos
Related Content
